Drug Trial Radar · NCT06073119
A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis
Last checked: Nov 19, 2026Latest source record: Nov 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
221
Actual
Start
Oct 26, 2023
Primary completion
Nov 13, 2024
Study completion Dec 11, 2024
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Oct 10, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a Phase 2, international, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, 12-week study. It was designed to assess the therapeutic dose, efficacy, and safety of treatment with SAR441566 in male and female adults with moderate to severe plaque psoriasis. Study details included a screening period (4 weeks and not less than 11 days before Day 1), a treatment period (12 weeks ± 3 days) and a post-treatment period (safety follow-up) (4 weeks ± 3 days). The total number of study visits was 7.
Conditions
- Psoriasis
Interventions
SAR441566Drug
Tablet
PlaceboDrug
Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With a 75% or Greater Psoriasis Area and Severity Index (PASI) Score Reduction From Baseline (PASI75) at Week 12Time frame: Baseline (Day 1) and Week 12
Locations
51 sites in 17 countries. Site status is shown where the registry gives one.
Scottsdale Clinical Trials Site Number : 8400025
Scottsdale, Arizona
Dermatology Research Associates- Site Number : 8400019
Los Angeles, California
Daxia Trials Site Number : 8400022
Boca Raton, Florida
Renaissance Research and Medical Group, Inc- Site Number : 8400018
Cape Coral, Florida
Driven Research, LLC- Site Number : 8400012
Coral Gables, Florida
FXM Clinical Research Ft. Lauderdale, LLC Site Number : 8400015
Fort Lauderdale, Florida
Direct Helpers Medical Center Inc- Site Number : 8400023
Hialeah, Florida
FXM Clinical Research Miami, LLC- Site Number : 8400016
Miami, Florida
Center for Clinical Studies, LTD. LLP- Site Number : 8400007
Houston, Texas
Center for Clinical Studies, LTD, LLP- Site Number : 8400013
Webster, Texas
Jordan Valley Dermatology Center- Site Number : 8400027
South Jordan, Utah
Investigational Site Number : 0320003
CABA, Buenos Aires, Argentina
Investigational Site Number : 0320001
Buenos Aires, Buenos Aires F.D., Argentina
Investigational Site Number : 0320002
CABA, Buenos Aires F.D., Argentina
Investigational Site Number : 1000001
Sofia, Bulgaria
Investigational Site Number : 1240006
London, Ontario, Canada
Investigational Site Number : 1240002
Waterloo, Ontario, Canada
Investigational Site Number : 1520003
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 1520001
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 1520004
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 1520002
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 1560001
Hangzhou, China
Investigational Site Number : 1560002
Wuxi, China
Investigational Site Number : 2030003
Brno, Czechia
Investigational Site Number : 2680002
Batumi, Georgia
Investigational Site Number : 2680001
Tbilisi, Georgia
Investigational Site Number : 2760004
Blankenfelde-Mahlow, Germany
Investigational Site Number : 2760001
Frankfurt am Main, Germany
Investigational Site Number : 2760002
Witten, Germany
Investigational Site Number : 3480003
Budapest, Hungary
Investigational Site Number : 3480002
Debrecen, Hungary
Investigational Site Number : 3920005
Ichikawa-shi, Japan
Investigational Site Number : 3920001
Yokohama, Japan
Investigational Site Number : 3920004
Kamimashiki Gun, Kumamoto, Japan
Investigational Site Number : 3920003
Sakai-shi, Osaka, Japan
Investigational Site Number : 3920006
tabashi City, Tokyo, Japan
Investigational Site Number : 3920002
Tachikawa-shi, Tokyo, Japan
Investigational Site Number : 4800001
Quatre Bornes, Mauritius
Investigational Site Number : 6160001
Bydgoszcz, Poland
Investigational Site Number : 6160002
Katowice, Poland
Showing 40 of 51 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.